SCYX SCYNEXIS Inc: Enterprise Value-to-Revenue Multiple

SCYNEXIS Inc (SCYX) - corporate logo

SCYNEXIS, Inc. (SCYX) has evolved into a high-yield asset, generating net royalties from Brexafemme sales without capital expenditures. The enterprise value-to-revenue multiple illustrates the valuation trend, where -922.14 reflects the latest level of the metric. However, geopolitical strife is limiting drug exports. Meanwhile, an alliance with a pharma behemoth minimizes trade expenses, helping the company successfully withstand pressure from low-cost generics.

SCYX: SCYNEXIS Inc Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/19/2026

SCYNEXIS - analytical breakdowns and key metrics (SCYX)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental valuation:SCYX, Scynexis
Original product of scynexis.com

SCYNEXIS, Inc. (SCYX) specializes in the development of innovative triterpenoids to combat resistant fungal infections, offering the unique drug Brexafemme to the market. The current value of -922.14 reflects the enterprise value minus net debt relative to sales volume, allowing the enterprise value-to-revenue ratio to filter out speculative noise and assess the real value of assets and intellectual property.